- Home
- HCKT vs XNCR Comparison
HCKT vs XNCR Comparison
Compare HCKT & XNCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HCKT
- XNCR
- Stock Information
- Founded
- HCKT 1991
- XNCR 1997
- Country
- HCKT United States
- XNCR United States
- Employees
- HCKT N/A
- XNCR N/A
- Industry
- HCKT Professional Services
- XNCR Biotechnology: Pharmaceutical Preparations
- Sector
- HCKT Consumer Discretionary
- XNCR Health Care
- Exchange
- HCKT Nasdaq
- XNCR Nasdaq
- Market Cap
- HCKT 636.1M
- XNCR 547.8M
- IPO Year
- HCKT 1998
- XNCR 2013
- Fundamental
- Price
- HCKT $20.69
- XNCR $10.03
- Analyst Decision
- HCKT Strong Buy
- XNCR Buy
- Analyst Count
- HCKT 3
- XNCR 10
- Target Price
- HCKT $29.67
- XNCR $20.22
- AVG Volume (30 Days)
- HCKT 241.6K
- XNCR 862.2K
- Earning Date
- HCKT 11-03-2025
- XNCR 11-05-2025
- Dividend Yield
- HCKT 2.32%
- XNCR N/A
- EPS Growth
- HCKT N/A
- XNCR N/A
- EPS
- HCKT 0.59
- XNCR N/A
- Revenue
- HCKT $309,265,000.00
- XNCR $146,929,000.00
- Revenue This Year
- HCKT $2.33
- XNCR $23.31
- Revenue Next Year
- HCKT $4.84
- XNCR N/A
- P/E Ratio
- HCKT $35.01
- XNCR N/A
- Revenue Growth
- HCKT 3.98
- XNCR N/A
- 52 Week Low
- HCKT $19.39
- XNCR $6.92
- 52 Week High
- HCKT $34.02
- XNCR $27.24
- Technical
- Relative Strength Index (RSI)
- HCKT 45.68
- XNCR 74.51
- Support Level
- HCKT $20.32
- XNCR $8.49
- Resistance Level
- HCKT $21.04
- XNCR $8.73
- Average True Range (ATR)
- HCKT 0.52
- XNCR 0.46
- MACD
- HCKT 0.08
- XNCR 0.16
- Stochastic Oscillator
- HCKT 41.82
- XNCR 94.02
About HCKT Hackett Group Inc (The).
The Hackett Group Inc is an IP platform-based Generative Artificial Intelligence (Gen AI) strategic consulting and executive advisory digital transformation firm. The Hackett Group provides dedicated expertise in Gen AI-enabled enterprise transformation services across the front, mid and back office areas, including its highly recognized Oracle, SAP, OneStream and Coupa implementation offerings. It operates in three segments Oracle Solutions, SAP Solutions, and Global S&BT. It generates the majority of its revenue from the Global S&BT segment in the United States.
About XNCR Xencor Inc.
Xencor Inc a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases. The company uses its XmAb technology platform to create antibody product candidates. Its pipeline includes XmAb819, XmAb541, XmAb808, XmAb942, Plamotamab, and XmAb657. The group earns its revenue from collaboration agreements, product licensing agreements, and technology licensing agreements.